The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic ...

Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes ...

Personalis aims to lead the MRD liquid biopsy market with ultra-sensitive sequencing and upcoming Medicare coverage. Read here for more on PSNL stock.

SEATTLE - Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a biotechnology company focused on understanding the adaptive immune system, announced that its clonoSEQ test for measurable residual ...

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...

Natera shows strong oncology growth, 35% revenue surge, 54% test volume rise, higher expenses and 18% overvaluation at 15x ...

About BioNexus Gene Lab Corp. BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a precision diagnostics company focused on Southeast Asia. BGLC operates laboratories and partnerships across the region and is ...